About: No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://onlinelibrary.wiley.com/doi/10.1002/hon.2091/abstract
Description	This multicentre study focused on monitoring imatinib mesylate(IMA)trough plasma(Ctrough) and intracellular (IMA Cintrac) concentrations in 228 chronic myelogenous leukaemia patients. We found a correlation between IMA Ctrough and alpha 1-acid glycoprotein plasma concentrations. All other analysed parameters revealed only weak (gender, dose of IMA per kg) or not significant (age, albumin, creatinine plasma concentration or bodymass index) impact onmeasured IMA Ctrough. The IMA Ctrough decreased during the first 6months and significantly increased later during treatment. The IMA Ctrough at the first month of therapy did not differ between patients with and without an optimal response at the 12th (p = 0.724) and 18th month (p = 0.135) of therapy. The IMA Cintrac during the first month were not different between patients with and without an optimal response at the 6th (p=0.273) and the 12th month (p = 0.193) of therapy. This multicentre study focused on monitoring imatinib mesylate(IMA)trough plasma(Ctrough) and intracellular (IMA Cintrac) concentrations in 228 chronic myelogenous leukaemia patients. We found a correlation between IMA Ctrough and alpha 1-acid glycoprotein plasma concentrations. All other analysed parameters revealed only weak (gender, dose of IMA per kg) or not significant (age, albumin, creatinine plasma concentration or bodymass index) impact onmeasured IMA Ctrough. The IMA Ctrough decreased during the first 6months and significantly increased later during treatment. The IMA Ctrough at the first month of therapy did not differ between patients with and without an optimal response at the 12th (p = 0.724) and 18th month (p = 0.135) of therapy. The IMA Cintrac during the first month were not different between patients with and without an optimal response at the 6th (p=0.273) and the 12th month (p = 0.193) of therapy. (en)
Title	No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia (en)
skos:prefLabel	No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia (en)
skos:notation	RIV/00216224:14740/14:00074752!RIV15-MSM-14740___
http://linked.open...avai/riv/aktivita	P
http://linked.open...avai/riv/aktivity	P(ED1.1.00/02.0068)
http://linked.open...iv/cisloPeriodika	2
http://linked.open...vai/riv/dodaniDat	2015
http://linked.open...aciTvurceVysledku	Žáčková, Daniela Mužík, Jan Ráčil, Z. Mayer, Jiří Zdráhal, Zbyněk Potěšil, David
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Masarykova univerzita / Středoevropský technologický institut
http://linked.open...dnocenehoVysledku	32673
http://linked.open...ai/riv/idVysledku	RIV/00216224:14740/14:00074752
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	CML; imatinib; plasma concentration; cell-asscociated concentration (en)
http://linked.open.../riv/klicoveSlovo	CML plasma concentration imatinib cell-asscociated concentration
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[BD9476DC3EEF]
http://linked.open...i/riv/nazevZdroje	Hematological Oncology
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	6 (xsd:int)
http://linked.open...cetTvurcuVysledku	15 (xsd:int)
http://linked.open...vavai/riv/projekt	Central european institute of technology
http://linked.open...UplatneniVysledku	2014
http://linked.open...v/svazekPeriodika	32
http://linked.open...iv/tvurceVysledku	Mayer, Jiří Rázga, Filip Ráčil, Zdeněk Suttnar, Jiří Zdráhal, Zbyněk Voglová, Jaroslava Žáčková, Daniela Mužík, Jan Potěšil, David Malásková, Ludmila Belohlavkova, Petra Dyr, Jan Klamova, Hana Malakova, Jana Polakova, Katerina Machova
http://linked.open...ain/vavai/riv/wos	000340570100005
issn	0278-0232
number of pages	7 (xsd:int)
http://bibframe.org/vocab/doi	10.1002/hon.2091
http://localhost/t...ganizacniJednotka	14740

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software